Biotech Reagents Ordering >> Full Product List >>

Description:

Human Insulin-like Growth Factor-II (Human IGF-II) is synthesized as a 156 amino acid precursor protein, known as proIGF-II. This protein includes an 87 amino acid C-terminal region known as the E-domain. A proteolysis step releases the mature 67 amino acid IGF-II polypeptide. The proIGF-II proteins make up 10-20% of circulating IGF-II. Pro-IGF-II proteins are secreted by some tumor cell lines and levels are elevated in non-islet cell tumor hypoglycemia.

References:

Duguay S. J. et al. (1998) J . Biol. Chem. 273, 18443-18451.

Source:

Produced recombinantly in E.coli.

Purity:

> 85 % (determined by HPLC and N-terminal sequence analysis).

Molecular Weight:

The final product contains three major isoforms of proIGF-II corresponding to molecular weights of 16.1, 17.0 and 17.6 kDa.
These species correspond to the full length 156 amino acid protein and two smaller species corresponding to C-terminal truncations of approximately 5 and 15 residues which result from the purification process.

N-terminal sequence analysis:

5 residues > 85 % single sequence

Biological Activity:

Stimulation of protein synthesis in rat L6 myoblasts.

Endotoxin:

< 0.1 EU/µg

State and Appearance:

Lyophilized white powder.
Dried from 0.1 M acetic acid and stored under dry nitrogen at a slight vacuum (-25 kPa)

Storage/Stability:

At least 2 years at 2 - 4°C (lyophilized).

Detection:

By Western blot

Reconstitution:

#1000: Handling of Novozymes GroPep IGF-I, IGF-II and IGF Analogs

Protocol:

#3009: Procedure for Western Immunoblotting human ProIGF-II

Related Products:

Human proIGF-II (aa 1-104)

IGF-IIE, (aa 138 - 156), anti-human

IGF-IIE, (aa 89 - 101), anti-human

IGF-IIE, (aa 78 - 88), anti-human